DHODH and cancer: Rationally designed nanoparticles and nanozymes that co-deliver DHODH inhibitors alongside ferroptosis inducers or immunotherapeutics have demonstrated remarkable potency in preclinical cancer models by simultaneously disabling multiple ferroptosis defense arms [17,23].